Company research
IMV Inc.
CIK 1734768Updated Sep 26, 2026
Securities
Historical securities (1)
IMVIQ · NYSE_ARCA · equity · closed Jun 24, 2024Name history
Immunovaccine Inc. · through May 1, 2018
IMVIQ price & chart
Historical security
This listing closed Jun 24, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -37,991,000Source | -36,589,000Source | -34,855,000Source | -27,365,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -125,000Source | 972,000Source | -1,067,000Source | 492,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -150,000Source | 970,000Source | 1,779,000Source | -1,418,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | 1,738,000Source | 1,005,000Source | 1,138,000Source |
| GeneralAndAdministrativeExpenseUSD | 16,986,000Source | 16,020,000Source | 15,205,000Source | 10,140,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 2,236,000Source | — | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 228,000Source | 114,000Source | 106,000Source | 90,000Source |
| ProceedsFromIssuingSharesCAD | — | — | 25,082,000Source | 29,456,000Source |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Total RevenueUSD | — | 188,000Source | 301,000Source | 568,000Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,343,455Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,343,455Source | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.29Source | 0.29Source | 0.29Source | 0.3Source |
| BasicEarningsLossPerShareUSD per share | -4.55Source | — | — | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | -172Source | — | — | — |
| DilutedEarningsLossPerShareUSD per share | -4.55Source | — | — | — |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedUSD | — | 16,000Source | 20,000Source | 20,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesUSD | — | 146,000Source | 170,000Source | 161,000Source |
| GeneralAndAdministrativeExpenseUSD | 16,986,000Source | 16,020,000Source | 15,205,000Source | 10,140,000Source |
| InterestExpenseUSD | 2,336Source | 907,000Source | 36,000Source | 1,239,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 139,000Source | — | — | — |
| ProfessionalFeesExpenseUSD | — | 2,499,000Source | 2,488,000Source | 1,779,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -37,991,000Source | — | — | — |
| ProfitLossBeforeTaxUSD | -37,991,000Source | -36,589,000Source | -34,855,000Source | -27,365,000Source |
| ResearchAndDevelopmentExpenseUSD | 23,281,000Source | 23,080,000Source | 26,605,000Source | 18,986,000Source |
| RevenueFromInterestUSD | 329,000Source | 188,000Source | 298,000Source | 509,000Source |